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Xeroderma pigmentosum (XP) is an autosomal recessive genetic 
disorder with the following conditions: neurologic disorders that 
gradually progress and skin hypersensitivity to ultraviolet (UV). 
Inhalational anesthetic drugs should be avoided in these patients since 
they may induce DNA damage, also use of muscle relaxants should be 
kept to a minimum. Thus for XP patients, total intravenous anesthesia 
(TIVA) is more appropriate for inducing general anesthesia and airway 
manipulation must be kept to a minimum. We report a 6 year old boy 
with XP and its airway management and anesthesia during surgery. 
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Introduction
Xeroderma pigmentosum (XP) is an autosomal 
recessive genetic disorder 1 with the following 
conditions: neurologic disorders that gradually 
progress, ocular involvement and skin 
hypersensitivity to sunlight. 2 
The incidence varies considerably in different parts 
of the world, the lowest being in Western Europe 
and the highest being in North Africa and the 
Middle East. 3 It is believed that volatile anesthetics 
may induce DNA damage in the cells of patients 
with XP and aggravate their symptoms, 4  although 
no human data exist regarding this effect up to 
now. 5  Minimum muscle relaxation is used during 
the operation. Patients with XP may have difficult 
airway. 6 
Case Presentation
A 6-year-old boy with XP was referred to our 
institute for excisional biopsies of several malignant 
skin tumors. Since he was three years old he had 
extensive brown skin lesions and tumors. The 
tumors near the orbit and the lower eyelid required 
excisional biopsy and were replaced by skin grafts 
from the medial region of the right arm. In primary 
evaluation, he was completely alert and oriented. 
He had no prior medical history of neurological 
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by Kaposi; it presents itself in childhood and 
has premalignant and malignant lesions which 
eventually lead to death in adulthood. These 
patients have many types of abnormalities such 
as facial and oropharyngeal defects which lead to 
difficult intubation, prolongation of neuromuscular 
blockade and also the fact that they cannot tolerate 
inhalation anesthetic agents drugs; all result in 
their anesthesia being complicated. 
In XP patients, using inhalation anesthetic agents 
such as halothane result in worsening of the 
symptoms of XP by deranging Nucleotide Excision 
Repair (NER) in cells; thus general anesthesia using 
volatile agents should be avoided if possible 9  and 
intravenous agents should be used instead. Also 
due to neuronal and muscular dysfunction in XP 
patients they are very sensitive to neuromuscular 
blocking drugs and the use of muscle relaxants 
should be minimal. 10  In this case having in mind 
the risk of difficult laryngoscopy and intubation 
we used LMA and opted for intravenous general 
anesthesia. Airway manipulation was minute and 
the surgery was uneventful.
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signs and symptoms seizures. When evaluating 
the airway, mouth opening was limited also he had 
a grade II Mallampati but there were no mucosal 
lesions.  
Premedication was performed using IV midazolam 
and Fentanyl. Monitoring was carried out using 
pulse oximetry, ECG and blood pressure. Pre-
oxygenated was performed with 100% oxygen for 
about 3 minutes. Induction was carried out using 
lidocaine and propofol. LMA size 2 was used for 
intubation and proper placement was confirmed 
by auscultation over the neck. 7 Maintenance of 
anesthesia was achieved with N2O 50%, O2 50% 
and propofolremifentanil infusion. He did not 
receive any muscle relaxants and had spontaneous 
ventilation. He did not experience any adverse 
effect during the operation or recovery Figure1.
Figure 1: Patient under anesthesia
 Discussion
Xeroderma pigmentosum is an autosomal recessive 
genetic disorder with its unique characteristics 
being: neurological disorders, very high risk of 
skin cancer and hypersensitivity to sunlight.8 
This disorder was originally described in 1870 
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